| Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis AJ Templeton, MG McNamara, B Šeruga, FE Vera-Badillo, P Aneja, ... Journal of the National Cancer Institute 106 (6), dju124, 2014 | 3228 | 2014 |
| Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab S Diem, S Schmid, M Krapf, L Flatz, D Born, W Jochum, AJ Templeton, ... Lung cancer 111, 176-181, 2017 | 910 | 2017 |
| Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis AJ Templeton, O Ace, MG McNamara, M Al-Mubarak, FE Vera-Badillo, ... Cancer epidemiology, biomarkers & prevention 23 (7), 1204-1212, 2014 | 786 | 2014 |
| Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis JL Ethier, D Desautels, A Templeton, PS Shah, E Amir Breast Cancer Research 19, 1-13, 2017 | 662 | 2017 |
| Neutrophils in cancer: prognostic role and therapeutic strategies A Ocana, C Nieto-Jiménez, A Pandiella, AJ Templeton Molecular cancer 16, 1-7, 2017 | 463 | 2017 |
| Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ... Journal of the National Cancer Institute 106 (1), djt319, 2014 | 422 | 2014 |
| Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic GS Kulkarni, T Hermanns, Y Wei, B Bhindi, R Satkunasivam, ... Journal of clinical oncology 35 (20), 2299-2305, 2017 | 323 | 2017 |
| HER3 overexpression and survival in solid tumors: a meta-analysis A Ocana, F Vera-Badillo, B Seruga, A Templeton, A Pandiella, E Amir JNCI: Journal of the National Cancer Institute 105 (4), 266-273, 2013 | 258 | 2013 |
| Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer I Cima, R Schiess, P Wild, M Kaelin, P Schüffler, V Lange, P Picotti, ... Proceedings of the National Academy of Sciences 108 (8), 3342-3347, 2011 | 230 | 2011 |
| Systemic therapy for non–clear cell renal cell carcinomas: a systematic review and meta-analysis FE Vera-Badillo, AJ Templeton, I Duran, A Ocana, P de Gouveia, P Aneja, ... European urology 67 (4), 740-749, 2015 | 229 | 2015 |
| Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of … D Lorente, J Mateo, AJ Templeton, Z Zafeiriou, D Bianchini, ... Annals of Oncology 26 (4), 750-755, 2015 | 218 | 2015 |
| Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis A Ocana, F Vera-Badillo, M Al-Mubarak, AJ Templeton, ... PloS one 9 (4), e95219, 2014 | 189 | 2014 |
| Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy AJ Templeton, JJ Knox, X Lin, R Simantov, W Xie, N Lawrence, R Broom, ... European urology 70 (2), 358-364, 2016 | 176 | 2016 |
| Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio AJ Templeton, C Pezaro, A Omlin, MG McNamara, R Leibowitz‐Amit, ... Cancer 120 (21), 3346-3352, 2014 | 165 | 2014 |
| Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of … AJ Templeton, FE Vera-Badillo, L Wang, M Attalla, P De Gouveia, ... Annals of oncology 24 (12), 2972-2977, 2013 | 160 | 2013 |
| Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two … RJ Van Soest, AJ Templeton, FE Vera-Badillo, F Mercier, G Sonpavde, ... Annals of Oncology 26 (4), 743-749, 2015 | 158 | 2015 |
| Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) AJ Templeton, V Dutoit, R Cathomas, C Rothermundt, D Bärtschi, ... European urology 64 (1), 150-158, 2013 | 149 | 2013 |
| Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer S Gillessen, A Templeton, G Marra, YF Kuo, E Valtorta, VB Shahinian Journal of the National Cancer Institute 102 (23), 1760-1770, 2010 | 145 | 2010 |
| Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09) C Rothermundt, S Hayoz, AJ Templeton, R Winterhalder, RT Strebel, ... European urology 66 (3), 468-474, 2014 | 140 | 2014 |
| Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer MG McNamara, AJ Templeton, M Maganti, T Walter, AM Horgan, ... European Journal of Cancer 50 (9), 1581-1589, 2014 | 139 | 2014 |
